Total equity has increased to EUR10.3 million, as reported at the end of 2024. The earnings call transcript provides more details. The EVX-01 vaccine mainly triggers CD4 T cells with some CD8 T cell response.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing